If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Patients with ankylosing spondylitis are associated with an increased risk of developing neurodegenerative diseases, ...
News Medical on MSN4d
Bioactive compounds in coffee and tobacco may combat Parkinson’s diseaseTobacco and coffee contain bioactive compounds that may reduce Parkinson's disease risk by targeting key pathways such as MAO ...
An expert panel has developed a hospital care plan for Parkinson disease to avoid preventable harm among patients.
The following is a summary of “Expanded and independent validation of the NoMoFA scale for Parkinson’s disease: the Italian ...
PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • ...
Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...
The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...
The following is a summary of “Pain in Parkinson's disease is impacted by motor complications, anxiety and sleep disturbances ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback